MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation

In this issue of Cancer Discovery , Adams and colleagues present the discovery of a potent PROTAC, MDM2 degrader, which activates wild-type p53 leading to cancer cell death. Importantly, in a number of in vitro and in vivo experiments, the authors show that the depletion of MDM2 by PROTAC kills p53-mutant or p53-null cancer cells.

Automated summary

In this issue of Cancer Discovery, Adams and colleagues report the discovery of a powerful PROTAC, MDM2 degrader, which activates wild-type p53 and induces cancer cell death. They demonstrate through in vitro and in vivo experiments that the depletion of MDM2 by PROTAC effectively kills p53-mutant or p53-null cancer cells.